Madrigal Pharmaceuticals, Inc.
MDGL
Rangering i aksjer
#1976
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical... Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Aksjekurs
$468.54
Markedsverdi
$10.83B
Endring (1 dag)
4.80%
Endring (1 år)
6.49%
Land
US
Handel Madrigal Pharmaceuticals, Inc. (MDGL)
Kategori
Healthcare
Historikk for aksjesplitt for Madrigal Pharmaceuticals, Inc. (MDGL)
Aksjen Madrigal Pharmaceuticals, Inc. (symbol: MDGL) har gjennomgått totalt 1 aksjesplitt.
Den nyeste splittelsen skjedde Jul 25, 2016.
Én MDGL-aksje kjøpt før Jul 25, 2016 tilsvarer i dag 0.028571428571429 MDGL-aksjer.
Den nyeste splittelsen skjedde Jul 25, 2016.
Én MDGL-aksje kjøpt før Jul 25, 2016 tilsvarer i dag 0.028571428571429 MDGL-aksjer.
Liste over aksjesplitt
| År | Splitt | Multiplikator | Kumulativ multiplikator |
|---|---|---|---|
| 2016-07-25 | 1:35 | x0.028571428571429 | x0.028571428571429 |
Aksjesplitt for lignende selskaper eller konkurrenter
| Selskap | Antall aksjesplitt | Kumulativ multiplikator | Land |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
